In Japan, which started the vaccination campaign in the face of the Covid-19 outbreak with healthcare professionals on February 17, and only approved for the use of the Pfizer-BioNTech vaccine so far, the expert board of the Ministry of Health gave 2 more vaccine manufacturers visas.
At the meeting held today, the board gave the green light to the vaccines developed by the US pharmaceutical company Moderna and the British-Swedish joint drug manufacturer AstraZeneca and Oxford University.
It was learned that the Moderna vaccine is expected to be used in the mass vaccination centers expected to open on Monday in Tokyo and Osaka under the leadership of the Self Defense Forces (SDF) in Japan.
THE NUMBER OF VACCINES APPROVED TO INCREASE TO 3
With the official permission of the Japanese Ministry of Health for AstraZeneca and Moderna vaccines tomorrow, the number of vaccines approved by the government in the country will increase to 3.
AstraZeneca and Moderna vaccines have been applied in many countries outside of Japan so far, and clinical trials in Japan revealed that both vaccines increase antibody production.
EXCEED 4 PERCENT OF THE POPULATION
In Japan, Covid-19 vaccination mobilization started with Pfizer-BioNTech vaccines on February 17.
While vaccination was started with healthcare workers, the program continued with the elderly population of 36 million as of mid-April. The fact that only about 4 percent of the 126 million population had reached at least one dose of vaccine has prompted criticism that mobilization should be accelerated. The government signaled that the vaccine approval process would be accelerated.
OFFER OF COVID-19 VACCINE FROM RUSSIA TO JAPAN
In the face of the Covid-19 epidemic, while the vaccination campaign continued at full speed around the world, vaccine support came from Russia to Japan.
Moscow’s Ambassador to Japan, Mikhail Galuzin, stated that his country is ready to provide the Russian-made Sputnik V Covid-19 vaccine to Tokyo.
Reiterating that Russia offered to support Japan in vaccine procurement earlier this year and expected a response, Galuzin said, “We are ready to cooperate with Japan on the Sputnik vaccine”.
Reminding that the Russian vaccine has been approved for use in approximately 65 countries and is produced locally in many countries, including India, Galuzin stated that they are ready for export to Japan and production in the country.
On the other hand, while the total number of Covid-19 cases in Japan increased to 705 thousand 931, the loss of life reached 12 thousand 62.